Patent details
LUC00097 Product Name: un anticorps se liant au B7-H1 comprenant une chaîne lourde CDR1 ayant la séquence d'acides aminés GFTFSRYWMS, une chaîne lourde CDR2 ayant la séquence d'acides aminés NIKQDGSEKYYVDSVKG, une chaîne lourde CDR3 ayant la séquence d'acides aminés EGGWFGELAFDY, une chaîne légère CDR1 ayant la séquence d'acides aminés RASQRVSSSYLA, une chaîne légère CDR2 ayant la séquence d'acides aminés DASSRAT et une chaîne légère CDR3 ayant la séquence d'acides aminés QQYGSLPWT, en particulier Durvalumab, ou une de ses variantes équivalentes thérapeutiquement telle que protégée par le brevet de base
Basic Information
- Publication number:
- LUC00097
- Type:
- SPC
- SPC Type:
- Medical
- Basic Patent Number:
- EP108339235
- Legal Status:
- Inactive
- Application number:
- LUC00097
- First applicant's nationality:
- Procedural language:
- French
Paediatric Extension
- SPC Extension Filing Date:
- 24/04/2024
- SPC Extension Agent Name:
- ARONOVA S.A.
- SPC Extension Status:
- Granted
- SPC Extension Grant Date:
- 04/08/2025
- SPC Extension Rejection Date:
Marketing Authorization
- Marketing Authorization Number:
- EU/1/18/1322
- Marketing Authorization Type:
- Marketing Authorization Date:
- 25/09/2018
- Marketing Authorization Status:
- Accepted
- Marketing Authorization Country:
- Luxembourg (LU)
Dates
- Filing date:
- 14/01/2019
- First Marketing Authorization date:
- 25/09/2018
- Grant date:
- 24/12/2019
- Activation date:
- Publication date:
- 14/01/2019
- Lapsed date:
- Expiration date:
- Renunciation date:
- Revocation date:
- Annulment date:
- Basic SPC Expiration:
- 25/09/2033
- SPC Extension Expiration:
- 25/03/2034
- Rejection date:
- Withdrawal date:
Owner
- From:
- 24/04/2024
- Name:
- MEDIMMUNE LIMITED
- Address:
- 1 Francis Crick Avenue Cambridge Biomedical Campus, CB2 0AA, Cambridge , United Kingdom (GB)
History of Owners
- From:
- 14/01/2019
- To:
- 24/04/2024
- Name:
- Medimmune Limited
- Address:
- Milstein Building Granta Park, Cambridge, Cambridgeshire CB21 6GH, United Kingdom (GB)
Agent
- Name:
- ARONOVA S.A.
- From:
- 14/01/2019
- Address:
- PO Box 327, L-4004, ESCH-SUR-ALZETTE, Luxembourg (LU)
- To:
Publication
Bulletin
1
- Bulletin Heading:
- SPC1
- Bulletin edition number:
- 2019/02
- Publication date:
- 22/02/2019
- Description:
- Section C : Published requests for Supplementary Protection Certificates – I1 publication
2
- Bulletin Heading:
- SPC2
- Bulletin edition number:
- 2020/01
- Publication date:
- 13/01/2020
- Description:
- Section D : Granted supplementary protection certificates – I2 publication
3
- Bulletin Heading:
- CO
- Bulletin edition number:
- 2024/06
- Publication date:
- 06/05/2024
- Description:
- Section M : Transfers of property (Art. 53 of the law), change of name and/or address
4
- Bulletin Heading:
- SPCX1
- Bulletin edition number:
- 2024/06
- Publication date:
- 06/05/2024
- Description:
- Section G : Applications for extensions for pediatric use – I1E publication
5
- Bulletin Heading:
- SPCX2
- Bulletin edition number:
- 2025/10
- Publication date:
- 05/09/2025
- Description:
- Section H : Granted extensions for pediatric use of supplementary protection certificates – I2E publication
Deed
Change of owner(s)
- Change Kind/ Decision Type:
- Change of owner(s) name/address
- Deed Number:
- RC20240000197A
- Date Registered:
- 24/04/2024
- Licence Effective Date:
- Licence Expiration Date:
- Scope of Licence:
- Deed Filer:
- ARONOVA S.A.
- Journal Edition Number:
- Text:
- Change of address
- Country Code:
- Updated Licence Number:
- Terminated Licence Number:
Added Owner(s)
- Name:
- MEDIMMUNE LIMITED
- Address:
- 1 Francis Crick Avenue Cambridge Biomedical Campus, CB2 0AA, Cambridge , United Kingdom (GB)
Removed Pledgee
- Name:
- Address:
Annual Fees
- Annual Fee Due Date:
- 02/12/2030
- Annual Fee Number:
- 21
- Annual Fee Amount:
- 410 Euro
- Expected Payer:
- Last Annual Fee Payment Date:
- Last Annual Fee Paid Number:
- Payer:
| Filing date | Document type | Number of pages |
|---|---|---|
| 04/08/2025 | Outgoing Correspondence | 1 |
| 07/08/2025 | Certificate | 2 |
| 07/08/2025 | Publication | 1 |
| 14/01/2019 | Outgoing Correspondence | 1 |
| 14/01/2019 | General Document | 2 |
| 24/04/2024 | Outgoing Correspondence | 1 |
| 24/04/2024 | Request For Change | 1 |
| 24/04/2024 | Application Form | 4 |
| 24/04/2024 | Marketing authorization | 3 |
| 24/04/2024 | MA publication | 9 |
| 24/04/2024 | Paediatric investigation plan | 1 |
| 24/04/2024 | Marketing authorization | 3 |
| 24/04/2024 | Summary of the product caracteristics | 74 |
| 24/04/2024 | FNET_DC_FRONTPAGE | 1 |
| 24/04/2024 | Publication | 1 |
| 24/04/2024 | Outgoing Correspondence | 1 |
| 14/01/2019 | Incoming Correspondence (Post) | 1 |
| 14/01/2019 | General Document | 2 |
| 24/12/2019 | Publication | 1 |
| 14/01/2019 | General Document | 2 |
| 14/01/2019 | Application Form | 4 |
| 14/01/2019 | Publication | 1 |
| 14/01/2019 | General Document | 4 |
| 24/12/2019 | Certificate | 2 |
| 08/11/2019 | Incoming Correspondence (Post) | 1 |
| 20/09/2019 | Incoming Correspondence (Post) | 1 |
| 24/12/2019 | Outgoing Correspondence | 1 |
| 14/01/2019 | General Document | 36 |